Related references
Note: Only part of the references are listed.Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
Karel G. M. Moons et al.
ANNALS OF INTERNAL MEDICINE (2015)
High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Ziad Hijazi et al.
CIRCULATION (2014)
Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Lars Wallentin et al.
CIRCULATION (2014)
Towards better clinical prediction models: seven steps for development and an ABCD for validation
Ewout W. Steyerberg et al.
EUROPEAN HEART JOURNAL (2014)
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy
Ziad Hijazi et al.
HEART (2014)
High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin
Ziad Hijazi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
Harvey D. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
External validation of a Cox prognostic model: principles and methods
Patrick Royston et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference
Paulus Kirchhof et al.
EUROPACE (2013)
Biomarkers in atrial fibrillation: a clinical review
Ziad Hijazi et al.
EUROPEAN HEART JOURNAL (2013)
N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation Insights From the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)
Ziad Hijazi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy
Ziad Hijazi et al.
CIRCULATION (2012)
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study
Leif Friberg et al.
EUROPEAN HEART JOURNAL (2012)
Moving the Tipping Point The Decision to Anticoagulate Patients With Atrial Fibrillation
Mark H. Eckman et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease
Harvey White et al.
AMERICAN HEART JOURNAL (2010)
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Renato D. Lopes et al.
AMERICAN HEART JOURNAL (2010)
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
Gregory Y. H. Lip et al.
CHEST (2010)
Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
A. John Camm et al.
EUROPEAN HEART JOURNAL (2010)
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Stuart J. Connolly et al.
CIRCULATION (2008)
Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Robert G. Hart et al.
ANNALS OF INTERNAL MEDICINE (2007)
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus
MA Bhalla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study)
PM Rothwell et al.
LANCET (2004)
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation
EM Hylek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation
BF Gage et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
AS Go et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
